​

Akari Therapeutics Stock (NASDAQ:AKTX)

ForecastRevenueOwnershipFinancialsChart
Akari Therapeutics by TradingView

Previous Close

$0.41

52W Range

$0.27 - $1.73

50D Avg

$0.65

200D Avg

$1.00

Market Cap

$6.95K

Avg Vol (3M)

$730.57K

Beta

0.28

Div Yield

-

AKTX Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

GB

Employees

8

IPO Date

Jan 06, 2014

Website

AKTX Performance

AKTX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-21.64M$-16.81M$-23.09M
Net Income$-19.79M$-10.01M$-6.97M
EBITDA$-21.64M$-16.80M$-23.08M
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 17Mar 21, 18 | 8:30 AM

Peer Comparison

TickerCompany
PPBTPurple Biotech Ltd.
XAGELongevity Health Holdings Inc.
MSPRMSP Recovery, Inc.
PBMPsyence Biomedical Ltd.
SYRSSyros Pharmaceuticals, Inc.
VRPXVirpax Pharmaceuticals, Inc.
CDTCDT Equity Inc.
VINCVincerx Pharma, Inc.
DRMADermata Therapeutics, Inc.
REVBRevelation Biosciences, Inc.